Real-world outcomes and immune-related adverse events in Canadian patients with non-small cell lung cancer receiving neoadjuvant platinum-based chemotherapy and nivolumab.
710 Background: Lung cancer is the leading cause of cancer-related mortality in Canada. Patients with resectable non-small cell lung cancer (NSCLC) can receive curative intent surgery, though relapse rates are high. The addition of nivolumab to neoadjuvant platinum-doublet chemotherapy has recently become the s...